Artificial heart technology company Scandinavian Real Heart AB (Nasdaq Stockholm First North Growth Market:HEART) announced on Wednesday that it has received patent approval from the European Patent Office for its Realheart TAH (Total Artificial Heart) technology.
The unitary patent, valid in 17 European Union countries including Sweden, France, and Germany, protects the device's core structure, function, and integrated feedback mechanism through 2041 (Patent No. 4120893).
Realheart TAH is designed to mimic the structure and function of the human heart and provide accurate, real-time pressure measurements. The patented sensor enables automated regulation of cardiac output, supporting artificial heart and circulatory systems.
The technology aims to offer a meaningful treatment alternative for patients awaiting heart transplants. Its structural design also seeks to reduce risks commonly associated with current artificial heart devices, such as stroke, internal bleeding, and anaemia.
GE HealthCare expands Vivid cardiovascular ultrasound portfolio with three new systems
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Revier Therapeutics closes EUR6m seed financing and launches operations
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
European Commission grants orphan designation for Lundbeck's asedebart
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
PTC to acquire BLA-stage ST-920 Fabry disease programme
Olio Labs reveals study demonstrating AI-driven in vivo platform can predict clinical trial outcomes
Mezzion Pharma Co reports positive results from new in vivo study of udenafil
Incyte's Opzelura approved in European Union for moderate atopic dermatitis